Pierre Massion
Faculty Member
Last active: 1/11/2018

  1. Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Stacy DR, Ely K, Massion PP, Yarbrough WG, Hallahan DE, Sekhar KR, Freeman ML (2006) Head Neck 28(9): 813-8
    › Primary publication · 16637057 (PubMed)
  2. Restoration of TGF-beta signalling reduces tumorigenicity in human lung cancer cells. Anumanthan G, Halder SK, Osada H, Takahashi T, Massion PP, Carbone DP, Datta PK (2005) Br J Cancer 93(10): 1157-67
    › Primary publication · 16251876 (PubMed) · PMC2361493 (PubMed Central)
  3. Proteomic patterns of preinvasive bronchial lesions. Rahman SM, Shyr Y, Yildiz PB, Gonzalez AL, Li H, Zhang X, Chaurand P, Yanagisawa K, Slovis BS, Miller RF, Ninan M, Miller YE, Franklin WA, Caprioli RM, Carbone DP, Massion PP (2005) Am J Respir Crit Care Med 172(12): 1556-62
    › Primary publication · 16179643 (PubMed) · PMC2718455 (PubMed Central)
  4. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Shinohara ET, Gonzalez A, Massion PP, Chen H, Li M, Freyer AS, Olson SJ, Andersen JJ, Shyr Y, Carbone DP, Johnson DH, Hallahan DE, Lu B (2005) Cancer 103(8): 1685-92
    › Primary publication · 15742356 (PubMed)
  5. Novel strategies for the early detection and prevention of lung cancer. Wardwell NR, Massion PP (2005) Semin Oncol 32(3): 259-68
    › Primary publication · 15988680 (PubMed)
  6. Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. Haruki N, Kawaguchi KS, Eichenberger S, Massion PP, Olson S, Gonzalez A, Carbone DP, Dang TP (2005) Cancer Res 65(9): 3555-61
    › Primary publication · 15867348 (PubMed)
  7. Cloned fusion product from a rare t(15;19)(q13.2;p13.1) inhibit S phase in vitro. Haruki N, Kawaguchi KS, Eichenberger S, Massion PP, Gonzalez A, Gazdar AF, Minna JD, Carbone DP, Dang TP (2005) J Med Genet 42(7): 558-64
    › Primary publication · 15994877 (PubMed) · PMC1736105 (PubMed Central)
  8. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart Salmon J, Kim YH, Pollack JR, Yanagisawa K, Gazdar A, Minna JD, Kurie JM, Carbone DP (2005) Cancer Res 65(1): 226-35
    › Primary publication · 15665299 (PubMed)
  9. Role of p63 amplification and overexpression in lung cancer development. Massion PP, Taflan PM, Rahman SM, Yildiz P, Shyr Y, Carbone DP, Gonzalez AL (2004) Chest 125(5 Suppl): 102S
    › Primary publication · 15136437 (PubMed)
  10. Nuclear survivin as a biomarker for non-small-cell lung cancer. Lu B, Gonzalez A, Massion PP, Shyr Y, Shaktour B, Carbone DP, Hallahan DE (2004) Br J Cancer 91(3): 537-40
    › Primary publication · 15266313 (PubMed) · PMC2409840 (PubMed Central)